250 related articles for article (PubMed ID: 7647026)
1. Management of vasospastic angina--role of nicorandil.
Kaski JC
Cardiovasc Drugs Ther; 1995 Mar; 9 Suppl 2():221-7. PubMed ID: 7647026
[TBL] [Abstract][Full Text] [Related]
2. Potassium channel activators in vasospastic angina.
Lablanche JM; Bauters C; McFadden EP; Quandalle P; Bertrand ME
Eur Heart J; 1993 Jul; 14 Suppl B():22-4. PubMed ID: 8370368
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of eccentric and concentric coronary stenosis vasomotion in patients with Prinzmental's variant angina and patients with stable angina pectoris.
Tousoulis D; Davies G; Kaski JC
Clin Cardiol; 1998 Sep; 21(9):643-8. PubMed ID: 9755380
[TBL] [Abstract][Full Text] [Related]
4. Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil.
Knight C; Purcell H; Fox K
Cardiovasc Drugs Ther; 1995 Mar; 9 Suppl 2():229-36. PubMed ID: 7647027
[TBL] [Abstract][Full Text] [Related]
5. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.
Frampton J; Buckley MM; Fitton A
Drugs; 1992 Oct; 44(4):625-55. PubMed ID: 1281076
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance relates to acetylcholine-induced microvascular vasoconstriction in a patient with vasospastic angina: potential implication of causalities between hyperinsulinemia and coronary microcirculation failure.
Oyama N; Urasawa K; Sakai H; Fujii S; Kitabatake A
Heart Vessels; 2005 Mar; 20(2):72-6. PubMed ID: 15772782
[TBL] [Abstract][Full Text] [Related]
7. Variant angina and coronary artery spasm: the clinical spectrum, pathophysiology, and management.
Kusama Y; Kodani E; Nakagomi A; Otsuka T; Atarashi H; Kishida H; Mizuno K
J Nippon Med Sch; 2011; 78(1):4-12. PubMed ID: 21389642
[TBL] [Abstract][Full Text] [Related]
8. Nicorandil: animal pharmacology.
Sakai K
Am J Cardiol; 1989 Jun; 63(21):2J-10J. PubMed ID: 2525321
[TBL] [Abstract][Full Text] [Related]
9. Nicorandil for angina.
Drug Ther Bull; 1995 Dec; 33(12):89-92. PubMed ID: 8777891
[TBL] [Abstract][Full Text] [Related]
10. Nicorandil: a potassium channel opening drug for treatment of ischemic heart disease.
Goldschmidt M; Landzberg BR; Frishman WH
J Clin Pharmacol; 1996 Jul; 36(7):559-72. PubMed ID: 8844437
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology and therapeutic effects of nicorandil.
Kinoshita M; Sakai K
Cardiovasc Drugs Ther; 1990 Aug; 4(4):1075-88. PubMed ID: 2150592
[TBL] [Abstract][Full Text] [Related]
12. Effect of nicorandil on coronary spasm.
Aizawa T; Ogasawara K; Nakamura F; Hirosaka A; Sakuma T; Nagashima K; Kato K
Am J Cardiol; 1989 Jun; 63(21):75J-79J. PubMed ID: 2525331
[TBL] [Abstract][Full Text] [Related]
13. Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina.
Chen JW; Lee WL; Hsu NW; Lin SJ; Ting CT; Wang SP; Chang MS
Am J Cardiol; 1997 Jul; 80(1):32-8. PubMed ID: 9205016
[TBL] [Abstract][Full Text] [Related]
14. Nicorandil for angina--an update.
Drug Ther Bull; 2003 Nov; 41(11):86-8. PubMed ID: 14658416
[TBL] [Abstract][Full Text] [Related]
15. [Anti-angina activity of potassium-channel activators].
Chiariello M; Duilio C; Ambrosio G
Cardiologia; 1993 Dec; 38(12 Suppl 1):459-63. PubMed ID: 8020048
[TBL] [Abstract][Full Text] [Related]
16. Calcium channel antagonists in the management of anginal syndromes: changing concepts in relation to the role of coronary vasospasm.
Opie LH
Prog Cardiovasc Dis; 1996; 38(4):291-314. PubMed ID: 8552788
[TBL] [Abstract][Full Text] [Related]
17. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study.
Ulvenstam G; Diderholm E; Frithz G; Gudbrandsson T; Hedbäck B; Höglund C; Moelstad P; Perk J; Sverrisson JT
J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S67-73. PubMed ID: 1282179
[TBL] [Abstract][Full Text] [Related]
18. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris.
Guermonprez JL; Blin P; Peterlongo F
Eur Heart J; 1993 Jul; 14 Suppl B():30-4. PubMed ID: 8370370
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview.
Roland E
Eur Heart J; 1993 Jul; 14 Suppl B():48-52. PubMed ID: 8370373
[TBL] [Abstract][Full Text] [Related]
20. A potassium channel opener as monotherapy in chronic stable angina pectoris: comparison with placebo.
Why HJ; Richardson PJ
Eur Heart J; 1993 Jul; 14 Suppl B():25-9. PubMed ID: 8370369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
